SynthesisJournal of clinical hypertension (Greenwich, Conn.)2026
Phenotype-Dependent Effect of Bedtime Antihypertensive Dosing on Nocturnal Blood Pressure: A Meta-Analysis Guided by Non-Dipper Prevalence.
Synthesis in Journal of clinical hypertension (Greenwich, Conn.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Bedtime dosing of antihypertensive medications is associated with a reduction in nocturnal blood pressure (BP), but whether this effect is modified at the study level remains uncertain. We conducted an updated meta-analysis of randomized controlled trials comparing bedtime versus morning antihypertensive administration, evaluating the overall treatment effect and its potential modification by baseline non-dipper prevalence. PubMed, EMBASE, and the Cochrane Library were searched, with nighttime ambulatory systolic BP (SBP) and diastolic BP (DBP) as primary outcomes. Subgroup analyses were performed based on baseline non-dipper proportion (< 60% vs. ≥ 60%). Sixty-six RCTs involving 29,654 participants were included. In the overall hypertensive population, bedtime dosing significantly reduced nighttime SBP (WMD: 4.87 mmHg; 95% CI: 3.75-6.00) and DBP (WMD: 2.80 mmHg; 95% CI: 2.23-3.37), with modest reductions in 24 h SBP (WMD: 2.06 mmHg) and daytime SBP (WMD: 0.99 mmHg). In trials restricted to non-dippers, a more pronounced reduction in nighttime BP was observed (SBP WMD: 7.57 mmHg; DBP WMD: 3.77 mmHg). Similarly, study populations with a higher baseline proportion of non-dippers (≥ 60%) experienced approximately two-fold higher nighttime SBP reductions versus those with lower prevalence (< 60%) (WMD: ∼9.7 vs. 4.4 mmHg; p < 0.01), with a consistent pattern for nighttime DBP (5.1 vs. 2.6 mmHg; between-group p < 0.05). Bedtime antihypertensive dosing reduces nocturnal BP across the general hypertensive population; however, the magnitude of effect appears to be modified at the study level by baseline non-dipper prevalence. These findings suggest that chronotherapy effects are heterogeneous across trial populations rather than uniform across all hypertensive individuals.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.